Viability of CLL Samples Exposed to Flavopiridol Expressed as Percentage of Viability Versus Control ± Standard Deviation
| Flavopiridol Concentration . | 4-h Exposure Then Washed and Viability Assessed at 4 d . | 1-d Exposure and Then Viability Assessed at 1 d . | 1-d Exposure Then Washed and Viability Assessed at 4 d . | 4-d Exposure and Then Viability Assessed at 4 d . |
|---|---|---|---|---|
| 0.01 μmol/L | 95.7 ± 11.1 | 100.64 ± 6.5 | 102.14 ± 13.9 | 110.95 ± 19.0 |
| 0.033 μmol/L | 76.87 ± 38.2 | 91.97 ± 8.2 | 105.48 ± 25.6 | 57.55 ± 58.7 |
| 0.1 μmol/L | 80.41 ± 39.7 | 72.99 ± 27.9 | 78.21 ± 25.5 | 53.91 ± 28.8 |
| 0.33 μmol/L | 69.91 ± 34.3 | 25.92 ± 11.1 | 15.47 ± 6.1 | 5.30 ± 28.8 |
| 1 μmol/L | 32.43 ± 22.6 | 24.11 ± 13.5 | 12.91 ± 4.3 | 8.19 ± 6.5 |
| 3.3 μmol/L | 13.10 ± 11.8 | 25.62 ± 11.6 | 11.46 ± 4.6 | 5.72 ± 9.0 |
| 10 μmol/L | 9.74 ± 12.6 | 24.27 ± 12.7 | 8.35 ± 4.4 | 6.91 ± 7.3 |
| 33 μmol/L | 9.22 ± 11.0 | 28.06 ± 13.7 | 10.31 ± 7.8 | 6.83 ± 8.64 |
| 100 μmol/L | 9.41 ± 11.1 | 23.64 ± 13.5 | 6.15 ± 3.4 | 4.58 ± 6.71 |
| Flavopiridol Concentration . | 4-h Exposure Then Washed and Viability Assessed at 4 d . | 1-d Exposure and Then Viability Assessed at 1 d . | 1-d Exposure Then Washed and Viability Assessed at 4 d . | 4-d Exposure and Then Viability Assessed at 4 d . |
|---|---|---|---|---|
| 0.01 μmol/L | 95.7 ± 11.1 | 100.64 ± 6.5 | 102.14 ± 13.9 | 110.95 ± 19.0 |
| 0.033 μmol/L | 76.87 ± 38.2 | 91.97 ± 8.2 | 105.48 ± 25.6 | 57.55 ± 58.7 |
| 0.1 μmol/L | 80.41 ± 39.7 | 72.99 ± 27.9 | 78.21 ± 25.5 | 53.91 ± 28.8 |
| 0.33 μmol/L | 69.91 ± 34.3 | 25.92 ± 11.1 | 15.47 ± 6.1 | 5.30 ± 28.8 |
| 1 μmol/L | 32.43 ± 22.6 | 24.11 ± 13.5 | 12.91 ± 4.3 | 8.19 ± 6.5 |
| 3.3 μmol/L | 13.10 ± 11.8 | 25.62 ± 11.6 | 11.46 ± 4.6 | 5.72 ± 9.0 |
| 10 μmol/L | 9.74 ± 12.6 | 24.27 ± 12.7 | 8.35 ± 4.4 | 6.91 ± 7.3 |
| 33 μmol/L | 9.22 ± 11.0 | 28.06 ± 13.7 | 10.31 ± 7.8 | 6.83 ± 8.64 |
| 100 μmol/L | 9.41 ± 11.1 | 23.64 ± 13.5 | 6.15 ± 3.4 | 4.58 ± 6.71 |